Aquinnah Pharmaceuticals receives $3.4 million grant from NINDS to advance new therapies for ALS

(MacDougall Biomedical Communications, Inc.) Aquinnah Pharmaceuticals, leaders in stress granule biology, an exciting new target for the development of neurodegenerative therapeutics, announced today that it has been awarded $3.4 million from the National Institute of Neurological Disorders and Stroke (NINDS) in a competing grant to advance novel therapeutic drug candidates towards the clinic for treating patients with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease.

Source: EurekAlert! - Biology - June 20, 2018 Category: Biology Source Type: news